Fact Source: Financial Supervisory Service DART / 2025-01-22
Disclosure Type: Earnings Forecast for Consolidated Financial Performance (Fair Disclosure)
💡 3-Second Summary
SAMSUNG BIOLOGICS has announced its consolidated revenue guidance for the full year of FY2025 at approximately KRW 5.57T, representing the median value of its projected annual top-line growth range of +20% to +25% year-over-year.
📊 1. [Key Disclosure Content & Major Figures Summary]
- FY2025 Consolidated Revenue Forecast: KRW 5,570,500,000,000 (KRW 5.57T)
- Target Period: January 1, 2025 ~ December 31, 2025
- Calculation Basis: Median value applied from the projected annual revenue expansion range of +20% to +25% relative to the prior year.
- Omitted Metrics: Estimates for operating profit, income before income tax, and net income for FY2025 are not specified in the official disclosure filing (-). Projections for FY2026 and FY2027 are also omitted.
- Basis of Forecast: Derived from internal management frameworks and forward-looking market demand projections.
- Historical Guidance Evaluation (FY2024 Verification):
- FY2024 Revenue Forecast: KRW 4.341T
- FY2024 Revenue Actual Performance: KRW 4.547T
- Guidance Deviation Error Rate: 4.7% (Actual performance exceeded the preliminary forecast)
- Regulatory Caveat: This document incorporates forward-looking information based on business plans and remains subject to potential variations depending on changes in the macroeconomic climate and dynamic market environments.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This fair disclosure serves as a corporate roadmap detailing the executive management’s official top-line target for the upcoming year, offering international macro players an indicator to gauge the company’s continuous growth velocity.
The primary fundamental highlight is the sustained upward trajectory of the corporation’s operational scale. The projected revenue of KRW 5.57T signals a corporate target to maintain a double-digit top-line growth rate of over 20% compared to the FY2024 finalized revenue of KRW 4.547T. While separate lines for projected operating profit or net margins are omitted from this template, the structural expansion of the revenue trajectory confirms that the baseline manufacturing framework remains in an scaling-up cycle.
Evaluating historical execution metrics adds support to this forecast, as evidenced by the tight 4.7% deviation rate recorded for FY2024. Keeping the variance under the 5% threshold documents that management’s internal projections carry a high degree of mathematical integrity rather than speculative overstatement. Because the filing does not detail the qualitative drivers behind this projected expansion—such as specific commercial asset utilization rates or near-term contract additions—investors should avoid definitive assumptions regarding final net yields and instead utilize this KRW 5.57T median baseline to cross-reference progressive quarterly milestone performance.
📝 Editor’s Comment (by K-STOCK Editor)
SAMSUNG BIOLOGICS has inaugurated the year by setting its annual revenue coordinates at KRW 5.57T for FY2025. Signaled as a +20% to +25% growth baseline, for a large-cap bellwether that has already established a multi-billion dollar revenue floor to target consecutive annual expansions above 20% highlights sustained market demand within the global CDMO landscape.
The essential takeaway from this ledger is the tight historic guidance error rate of 4.7% monitored during FY2024. This narrow gap proves that the numeric metrics distributed by the corporate IR department are rooted in precise calculation rather than generic placeholder metrics. While the omission of bottom-line net income projections prevents a precise calculation of near-term operating margins, achieving this degree of top-line scaling historically triggers positive operating leverage due to fixed cost distribution across production facilities. Rather than relying on short-term price predictions, global market participants should look at this KRW 5.57T target as a transparent metric to track successive quarterly conversion rates.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
